Bushen Huoxue Yiqi formula alleviates cardiac fibrosis in ischemic heart failure through SIRT1/Notch1 pathway-mediated EndMT.

Autor: Chen C; Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, No.5, beixiange, Xicheng District, Beijing 100053, China., Wang J; Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, No.5, beixiange, Xicheng District, Beijing 100053, China. Electronic address: wangjie0103@126.com., Hou C; Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, No.5, beixiange, Xicheng District, Beijing 100053, China., Lian W; Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, No.5, beixiange, Xicheng District, Beijing 100053, China., Zhu X; Department of Anatomy, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China., Hu J; Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, No.5, beixiange, Xicheng District, Beijing 100053, China., Liu C; Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, No.5, beixiange, Xicheng District, Beijing 100053, China.
Jazyk: angličtina
Zdroj: Phytomedicine : international journal of phytotherapy and phytopharmacology [Phytomedicine] 2024 Dec; Vol. 135, pp. 156252. Date of Electronic Publication: 2024 Nov 12.
DOI: 10.1016/j.phymed.2024.156252
Abstrakt: Background: Cardiac fibrosis plays a crucial role in the development of heart failure (HF) following myocardial infarction (MI). Endothelial-mesenchymal transition (EndMT) is one of the key drivers of cardiac fibrosis and subsequent cardiac dysfunction. The traditional Chinese medicine formula Bushen Huoxue Yiqi Formula (BHYF) is an effective prescription for treating HF, significantly improving cardiac function in patients. However, the underlying mechanisms of BHYF's efficacy remain inadequately understood.
Objective: This study aims to determine whether BHYF ameliorates HF by inhibiting cardiac fibrosis and to elucidate the intrinsic mechanisms involved.
Methods: A post-MI HF model was established by ligating the left anterior descending coronary artery in rats, and human umbilical vein endothelial cells (HUVEC) were stimulated with hypoxia/reoxygenation (H/R) in vitro. Active compounds in BHYF were identified using HPLC. Cardiac function and morphology were assessed using echocardiography, TTC staining, HE staining, Masson's trichrome, and Sirius Red staining. The mechanism of action of BHYF was evaluated using Western blotting, immunohistochemistry, and immunofluorescence.
Results: A total of 98 compounds, including glycosides, phenolic compounds, carboxylic acids, and others, were identified or preliminarily identified. BHYF improved cardiac function and myocardial damage in rats with MI-induced HF and mitigated cardiac fibrosis by inhibiting EndMT. Mechanistically, BHYF treatment inhibited EndMT by modulating the SIRT1/Notch1 pathway, thereby exerting anti-fibrotic effects in the heart.
Conclusion: Targeting EndMT based on the SIRT1/Notch1 pathway, BHYF may represent a novel antifibrotic therapeutic strategy, providing a scientific basis for the development of new cardiovascular drugs.
Competing Interests: Declaration of competing interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 The Author(s). Published by Elsevier GmbH.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: